Initial public offerings by biopharmaceutical companies continued to get back on track in the US with a $175m IPO from IGM Biosciences Inc. on 17 September, but Shanghai Henlius Biotech Inc. raised more than twice as much with an 18 September IPO in Hong Kong totaling nearly $410m.
Both companies are developing monoclonal antibodies, but while IGM is developing novel IgM antibodies, Henlius is focused on both new therapies and biosimilars
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?